Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
4.125
-0.105 (-2.48%)
At close: Mar 4, 2026, 4:00 PM EST
4.120
-0.005 (-0.12%)
After-hours: Mar 4, 2026, 4:12 PM EST
Prime Medicine Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 6.42, with a low estimate of 4.25 and a high estimate of 9.00. The average target predicts an increase of 55.64% from the current stock price of 4.13.
Analyst Consensus: Buy
* Price targets were last updated on Nov 11, 2025.
Analyst Ratings
The average analyst rating for Prime Medicine stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $5 → $4.25 | Hold | Maintains | $5 → $4.25 | +3.03% | Nov 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +118.18% | Nov 10, 2025 |
| Citigroup | Citigroup | Hold Maintains $1.5 → $4 | Hold | Maintains | $1.5 → $4 | -3.03% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +142.42% | Aug 8, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $10 → $1.5 | Strong Buy → Hold | Downgrades | $10 → $1.5 | -63.64% | May 27, 2025 |
Financial Forecast
Revenue This Year
5.34M
from 4.63M
Increased by 15.20%
Revenue Next Year
22.21M
from 5.34M
Increased by 316.23%
EPS This Year
-0.96
from -1.35
EPS Next Year
-0.89
from -0.96
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.5M | 141.8M | |||
| Avg | 5.3M | 22.2M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 126.7% | 2,556.5% | |||
| Avg | 15.2% | 316.2% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.59 | -0.37 | |||
| Avg | -0.96 | -0.89 | |||
| Low | -1.36 | -1.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.